# EDGAR Filing Document

**Accession Number:** 0001606498
**File Stem:** 0001606498-26-000063
**Filing Date:** 2026-5
**Character Count:** 129560
**Document Hash:** 73ec584ba7d424952259c2262e4d4a4c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001606498-26-000063.hdr.sgml**: 20260505

**ACCESSION NUMBER**: 0001606498-26-000063

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 80

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260505

**DATE AS OF CHANGE**: 20260505

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AVANOS MEDICAL, INC.
- **CENTRAL INDEX KEY:** 0001606498
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 464987888
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36440
- **FILM NUMBER:** 26942851

**BUSINESS ADDRESS:**
- **STREET 1:** 5405 WINDWARD PARKWAY
- **STREET 2:** SUITE 100 SOUTH
- **CITY:** ALPHARETTA
- **STATE:** GA
- **ZIP:** 30004
- **BUSINESS PHONE:** 844-428-2667

**MAIL ADDRESS:**
- **STREET 1:** 5405 WINDWARD PARKWAY
- **STREET 2:** SUITE 100 SOUTH
- **CITY:** ALPHARETTA
- **STATE:** GA
- **ZIP:** 30004

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Avanos Medical, Inc.
- **DATE OF NAME CHANGE:** 20180702

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Halyard Health, Inc.
- **DATE OF NAME CHANGE:** 20140424

?xml version='1.0' encoding='ASCII'? avns-20260331

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 10-Q** 

(Mark One)

☒&nbsp;&nbsp;&nbsp;&nbsp;**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2026** 

**OR**

☐&nbsp;&nbsp;&nbsp;&nbsp;**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from ________ to ________** 

**Commission File Number 001-36440** 

![avanoslogo.jpg](avns-20260331_g1.jpg)

**AVANOS MEDICAL, INC.** 

**(Exact name of registrant as specified in its charter)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Delaware** | **Delaware** | | | **46-4987888** |
| (State or other jurisdiction of incorporation) | (State or other jurisdiction of incorporation) | | | (I.R.S. Employer Identification No.) |
| | **5405 Windward Parkway** | **5405 Windward Parkway** | **5405 Windward Parkway** | **5405 Windward Parkway** |
| | **Suite 100 South** | **Suite 100 South** | **Suite 100 South** | **Suite 100 South** |
| | **Alpharetta,** | **Georgia** | **30004** | **30004** |
| | (Address of principal executive offices) | (Address of principal executive offices) | (Zip code) | (Zip code) |

---

Registrant's telephone number, including area code: **(844) 428-2667** 

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol | Name of exchange on which registered |
| **Common Stock - $0.01 Par Value** | **AVNS** | **New York Stock Exchange** |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Emerging growth company | ☐ |
| Smaller reporting company | ☐ | | |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐&nbsp;&nbsp;&nbsp;&nbsp;No ☒

As of April 28, 2026, there were 46,824,793 shares of the registrant's common stock outstanding.&nbsp;&nbsp;&nbsp;&nbsp;

------

**Table of Contents**

---

| | |
|:---|:---|
| <u>[PART I – FINANCIAL INFORMATION](#i3bee11a598f04c268992b039d8ab3883_13)</u> |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 1. Financial Statements](#i3bee11a598f04c268992b039d8ab3883_16)</u> | <u>[5](#i3bee11a598f04c268992b039d8ab3883_16)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Unaudited Condensed Consolidated Income Statements for the Three](#i3bee11a598f04c268992b039d8ab3883_19)[Months Ended](#i3bee11a598f04c268992b039d8ab3883_19)[March](#i3bee11a598f04c268992b039d8ab3883_19)[3](#i3bee11a598f04c268992b039d8ab3883_19)[1](#i3bee11a598f04c268992b039d8ab3883_19)[, 202](#i3bee11a598f04c268992b039d8ab3883_19)[6](#i3bee11a598f04c268992b039d8ab3883_19)[and 20](#i3bee11a598f04c268992b039d8ab3883_19)[25](#i3bee11a598f04c268992b039d8ab3883_19)</u> | <u>[5](#i3bee11a598f04c268992b039d8ab3883_19)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Unaudited Condensed Consolidated Statements of Comprehensive Income for the Three](#i3bee11a598f04c268992b039d8ab3883_22)[Months Ended](#i3bee11a598f04c268992b039d8ab3883_22)[March](#i3bee11a598f04c268992b039d8ab3883_22)[3](#i3bee11a598f04c268992b039d8ab3883_22)[1](#i3bee11a598f04c268992b039d8ab3883_22)[, 202](#i3bee11a598f04c268992b039d8ab3883_22)[6](#i3bee11a598f04c268992b039d8ab3883_22)[and 202](#i3bee11a598f04c268992b039d8ab3883_22)[5](#i3bee11a598f04c268992b039d8ab3883_22)</u> | <u>[6](#i3bee11a598f04c268992b039d8ab3883_22)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Unaudited Condensed Consolidated Balance Sheets as of](#i3bee11a598f04c268992b039d8ab3883_25)[March](#i3bee11a598f04c268992b039d8ab3883_25)[3](#i3bee11a598f04c268992b039d8ab3883_25)[1](#i3bee11a598f04c268992b039d8ab3883_25)[, 202](#i3bee11a598f04c268992b039d8ab3883_25)[6](#i3bee11a598f04c268992b039d8ab3883_25)[and December 31, 202](#i3bee11a598f04c268992b039d8ab3883_25)[5](#i3bee11a598f04c268992b039d8ab3883_25)</u> | <u>[7](#i3bee11a598f04c268992b039d8ab3883_25)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Unaudited Condensed Consolidated Statements of Stockholders' Equity for the Three](#i3bee11a598f04c268992b039d8ab3883_31)[Months Ended](#i3bee11a598f04c268992b039d8ab3883_31)[March](#i3bee11a598f04c268992b039d8ab3883_31)[3](#i3bee11a598f04c268992b039d8ab3883_31)[1](#i3bee11a598f04c268992b039d8ab3883_31)[, 202](#i3bee11a598f04c268992b039d8ab3883_31)[6](#i3bee11a598f04c268992b039d8ab3883_31)[and 202](#i3bee11a598f04c268992b039d8ab3883_31)[5](#i3bee11a598f04c268992b039d8ab3883_31)</u> | <u>[8](#i3bee11a598f04c268992b039d8ab3883_31)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Unaudited Condensed Consolidated Cash Flow Statements for the](#i3bee11a598f04c268992b039d8ab3883_34)[Three](#i3bee11a598f04c268992b039d8ab3883_34)[Months Ended](#i3bee11a598f04c268992b039d8ab3883_34)[March](#i3bee11a598f04c268992b039d8ab3883_34)[3](#i3bee11a598f04c268992b039d8ab3883_34)[1](#i3bee11a598f04c268992b039d8ab3883_34)[, 202](#i3bee11a598f04c268992b039d8ab3883_34)[6](#i3bee11a598f04c268992b039d8ab3883_34)[and 202](#i3bee11a598f04c268992b039d8ab3883_34)[5](#i3bee11a598f04c268992b039d8ab3883_34)</u> | <u>[9](#i3bee11a598f04c268992b039d8ab3883_34)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Notes to the Unaudited Condensed Consolidated Financial Statements](#i3bee11a598f04c268992b039d8ab3883_37)</u> | <u>[10](#i3bee11a598f04c268992b039d8ab3883_37)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#i3bee11a598f04c268992b039d8ab3883_106)</u> | <u>[23](#i3bee11a598f04c268992b039d8ab3883_106)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 3. Quantitative and Qualitative Disclosures About Market Risk](#i3bee11a598f04c268992b039d8ab3883_127)</u> | <u>[29](#i3bee11a598f04c268992b039d8ab3883_127)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 4. Controls and Procedures](#i3bee11a598f04c268992b039d8ab3883_130)</u> | <u>[30](#i3bee11a598f04c268992b039d8ab3883_130)</u> |
| <u>[PART II – OTHER INFORMATION](#i3bee11a598f04c268992b039d8ab3883_133)</u> | <u>[31](#i3bee11a598f04c268992b039d8ab3883_133)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 1. Legal Proceedings](#i3bee11a598f04c268992b039d8ab3883_136)</u> | <u>[31](#i3bee11a598f04c268992b039d8ab3883_136)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 1A. Risk Factors](#i3bee11a598f04c268992b039d8ab3883_139)</u> | <u>[31](#i3bee11a598f04c268992b039d8ab3883_139)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#i3bee11a598f04c268992b039d8ab3883_142)</u> | <u>[32](#i3bee11a598f04c268992b039d8ab3883_142)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 3. Defaults Upon Senior Securities](#i3bee11a598f04c268992b039d8ab3883_145)</u> | <u>[32](#i3bee11a598f04c268992b039d8ab3883_145)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 4. Mine Safety Disclosures](#i3bee11a598f04c268992b039d8ab3883_148)</u> | <u>[32](#i3bee11a598f04c268992b039d8ab3883_148)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 5. Other Information](#i3bee11a598f04c268992b039d8ab3883_151)</u> | <u>[32](#i3bee11a598f04c268992b039d8ab3883_151)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 6. Exhibits](#i3bee11a598f04c268992b039d8ab3883_154)</u> | <u>[33](#i3bee11a598f04c268992b039d8ab3883_154)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Signatures](#i3bee11a598f04c268992b039d8ab3883_157)</u> | <u>[34](#i3bee11a598f04c268992b039d8ab3883_157)</u> |

---

------

**Information Concerning Forward-Looking Statements**

This Quarterly Report on Form 10-Q (this "Form 10-Q") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are included throughout this Form 10-Q, including in the section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations." Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as "may," "believe," "will," "expect," "intend," "predict," "potential," "project," "estimate," "anticipate," "plan," or "continue" and similar expressions, among others. The matters discussed in these forward-looking statements are based on the current plans and expectations of our management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied in the forward-looking statements. These factors include, but are not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• general economic conditions, particularly in the United States;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• weakening of economic conditions that could adversely affect the level of demand for our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• fluctuations in global equity and fixed-income markets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our inability to complete our pending merger with certain affiliates of American Industrial Partners on the anticipated terms, or at all;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• potential adverse effects on our business and operations due to the pendency of the merger;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• provisions in the Agreement and Plan of Merger that may restrict our ability to pursue new opportunities or take other actions that might be beneficial to our business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to successfully execute on or achieve the expected benefits of our restructuring initiatives;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• supply chain issues and inflationary pressures;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a resurgence of the COVID-19 pandemic;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in the competitive environment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the loss of current customers or the inability to obtain new customers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• cybersecurity threats, including breaches of or cyberattacks on our information systems;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the ongoing regional conflicts between Russia and Ukraine and in the Middle East;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• concentration of our manufacturing operations in Mexico;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reductions in or eliminations of reimbursements from government healthcare programs or private health insurers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• financial conditions affecting the banking system and the potential threats to the solvency of commercial banks;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• litigation and enforcement actions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• disruption in the supply of raw materials or the distribution of finished goods;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• price fluctuations in key commodities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the expected impact of tariffs and our ability to mitigate tariffs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• new or increased tariffs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in, or revised interpretations of, import-export laws or international trade agreements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• fluctuations in currency exchange rates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in governmental regulations that are applicable to our business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to realize the intended benefits of our restructuring initiatives or our divestiture, acquisition or merger transactions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in asset valuations, including write-downs of assets such as inventory, accounts receivable or other assets for impairment or other reasons; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any other matters described in Item 1A - "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025 (the "Form 10-K") and Part II, Item 1A - "Risk Factors" in this Form 10-Q.

You are cautioned not to unduly rely on such forward-looking statements when evaluating the information in this Form 10-Q. Where, in any forward-looking statement, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of our management and expressed in good faith, and is believed to have a reasonable basis. There can be no assurance that any such expectation or belief will be achieved or accomplished.

------

Any forward-looking statement made in this Form 10-Q speaks only as of the date of this report. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable securities laws.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

**PART I – FINANCIAL INFORMATION**

**Item 1. &nbsp;&nbsp;&nbsp;&nbsp;Financial Statements**

**AVANOS MEDICAL, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED INCOME STATEMENTS**

**(in millions, except per share amounts)**

(Unaudited)

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **Net Sales** | $**182.2** | $167.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of products sold | **88.0** | 77.7 |
| **Gross Profit** | **94.2** | 89.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development | **5.2** | 5.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling and general expenses | **77.7** | 75.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other expense (income), net | **2.4** | (1.6) |
| **Operating Income** | **8.9** | 10.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income | **0.2** | 1.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense | **(1.5)** | (2.1) |
| **Income before income taxes** | **7.6** | 9.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax provision | **(2.5)** | (3.1) |
| **Net Income** | $**5.1** | $6.6 |
| **Earnings Per Share** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $**0.11** | $0.14 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $**0.11** | $0.14 |

---

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

**AVANOS MEDICAL, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME**

**(in millions)**

(Unaudited)

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **Net Income** | $**5.1** | $6.6 |
| **Other Comprehensive (Loss) Income, Net of Tax** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized currency translation adjustments | **(5.5)** | 2.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Defined benefit plans | **—** | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash flow hedges | **1.5** | (0.1) |
| **Total Other Comprehensive (Loss) Income, Net of Tax** | **(4.0)** | 2.3 |
| **Comprehensive Income** | $**1.1** | $8.9 |

---

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

**AVANOS MEDICAL, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(in millions, except share data)**

(Unaudited)

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| **ASSETS** | | |
| **Current Assets** | | |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $**65.6** | $89.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowances | **103.0** | 103.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | **141.3** | 148.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid and other current assets | **15.1** | 13.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Current Assets** | **325.0** | 355.4 |
| **Property, Plant and Equipment, net** | **111.2** | 113.4 |
| **Operating Lease Right-of-Use Assets** | **39.3** | 27.6 |
| **Goodwill** | **394.0** | 394.9 |
| **Other Intangible Assets, net** | **114.7** | 117.8 |
| **Deferred Tax Assets** | **33.0** | 33.1 |
| **Other Assets** | **32.9** | 31.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL ASSETS** | $**1050.1** | $1073.7 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| **Current Liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current portion of long-term debt | $**10.9** | $10.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current portion of operating lease liabilities | **10.4** | 8.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade accounts payable | **52.3** | 55.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | **57.6** | 91.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Current Liabilities** | **131.2** | 165.2 |
| **Long-Term Debt** | **87.3** | 90.3 |
| **Operating Lease Liabilities** | **29.8** | 20.4 |
| **Deferred Tax Liabilities** | **5.6** | 6.1 |
| **Other Long-Term Liabilities** | **14.1** | 13.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Liabilities** | **268.0** | 295.5 |
| **Commitments and Contingencies** |  |  |
| **Stockholders' Equity** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred stock - $0.01 par value - authorized 20,000,000 shares, none issued | **—** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock - $0.01 par value - authorized 300,000,000 shares, 46,673,069 outstanding as of March 31, 2026 and 46,456,462 outstanding as of December 31, 2025 | **0.5** | 0.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | **1696.0** | 1691.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | **(774.8)** | (779.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treasury stock | **(103.6)** | (102.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | **(36.0)** | (32.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Stockholders' Equity** | **782.1** | 778.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY** | $**1050.1** | $1073.7 |

---

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

**AVANOS MEDICAL, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY**

**(in millions)**

(Unaudited)

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **Common Stock** | $**0.5** | $0.5 |
| **Additional Paid-in Capital, beginning of period** | **1691.9** | 1678.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercise or redemption of share-based awards | **0.4** | 0.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | **3.7** | 3.8 |
| **Additional Paid-in Capital, end of period** | **1696.0** | 1682.8 |
| **Accumulated Deficit, beginning of period** | **(779.9)** | (707.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income | **5.1** | 6.6 |
| **Accumulated Deficit, end of period** | **(774.8)** | (700.4) |
| **Treasury Stock, beginning of period** | **(102.3)** | (99.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of treasury stock | **(1.3)** | (2.2) |
| **Treasury Stock, end of period** | **(103.6)** | (101.2) |
| **Accumulated Other Comprehensive Loss, beginning of period** | **(32.0)** | (44.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive (loss) income, net of tax | **(4.0)** | 2.3 |
| **Accumulated Other Comprehensive Loss, end of period** | **(36.0)** | (42.3) |
| **Total Stockholders' Equity, end of period** | $**782.1** | $839.4 |

---

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

**AVANOS MEDICAL, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED CASH FLOW STATEMENTS**

**(in millions)**

(Unaudited)

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **Operating Activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income | $**5.1** | $6.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | **10.2** | 9.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | **3.7** | 3.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss on asset dispositions | **0.1** | 0.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities, net of acquisition: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | **(0.3)** | 25.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | **6.1** | 1.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | **(2.4)** | 0.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | **(2.1)** | (6.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | **(33.7)** | (14.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes and other | **1.0** | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Cash (Used in) Provided by Operating Activities** | **(12.3)** | 25.7 |
| **Investing Activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures | **(4.3)** | (6.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments in non-affiliates | **(3.4)** | (2.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Cash Used in Investing Activities** | **(7.7)** | (9.1) |
| **Financing Activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Secured debt repayments | **(2.3)** | (2.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revolving credit facility repayments | **—** | (25.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of treasury stock | **(1.3)** | (2.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the exercise of stock options | **0.4** | 0.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Cash Used in Financing Activities** | **(3.2)** | (29.1) |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | **(1.0)** | 1.8 |
| **Decrease in Cash and Cash Equivalents** | **(24.2)** | (10.7) |
| **Cash and Cash Equivalents - Beginning of Period** | **89.8** | 107.7 |
| **Cash and Cash Equivalents - End of Period** | $**65.6** | $97.0 |

---

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

**AVANOS MEDICAL, INC. AND SUBSIDIARIES**

**NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**Note 1. Accounting Policies**

*Background and Basis of Presentation*

Avanos Medical, Inc. is a medical technology company focused on delivering clinically superior medical device solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, we are committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. We develop, manufacture and market our recognized brands globally and hold leading market positions in multiple categories across our portfolio. References herein to "Avanos," "the Company," "we," "our" and "us" refer to Avanos Medical, Inc. and its consolidated subsidiaries.

*Interim Financial Statements*

We prepared the accompanying unaudited condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements, and the condensed consolidated financial statements in this Form 10-Q should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2025. Our unaudited interim condensed consolidated financial statements contain all necessary material adjustments, which are of a normal and recurring nature, to fairly state our financial condition, results of operations and cash flows for the periods presented.

*Use of Estimates*

Preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting periods. Estimates are used in accounting for, among other things, certain amounts included in discontinued operations, distributor rebate accruals, future cash flows associated with impairment testing for goodwill and long-lived assets, valuations of assets and liabilities acquired in business combinations, loss contingencies, and deferred tax assets and potential income tax assessments. Actual results could differ from these estimates, and the effect of any change could be material to our financial statements. Changes in these estimates are recorded when known.

*Segment Reporting*

We follow the guidance in Accounting Standards Codification ("ASC") Topic 280, *Segment Reporting* as amended by Accounting Standards Update ("ASU") No. 2023-07, *Segment Reporting: Improvements to Reportable Segment Disclosures.* We define our reportable segments based on the way our Chief Operating Decision Maker ("CODM") manages the operations of the business for purposes of allocating resources and assessing performance. Our reportable segments are determined based on revenue, profit or loss and assets tests. We disclose segment revenue, operating income/loss and significant segment expenses for each reportable segment, which is consistent with our internal management reporting to the CODM.

See Note 4, "Segment Information" for disclosure of our reportable segments.

*Goodwill*

We test goodwill for impairment annually or more frequently whenever events or circumstances more likely than not indicate that the fair value of our reporting units may be below their respective carrying values. We operate as two operating and reportable segments. The fair values of our reporting units are estimated using a combination of income (discounted cash flow analysis) and market approaches. The income approach is dependent upon several assumptions regarding future periods such as sales growth and a terminal growth rate. A weighted average cost of capital ("WACC") was used to discount future estimated cash flows to their present values. The WACC was based on externally observable data considering market participants' cost of equity and debt, optimal capital structure and risk factors specific to us.

We determined that the fair value of our reporting units equaled or exceeded the net carrying amount in our most recent goodwill impairment test on July 1, 2025. However, there can be no assurance that the assumptions and estimates made for purposes of the annual goodwill impairment test will prove to be accurate. Volatility in the equity and debt markets, or increases in interest rates, could result in a higher discount rate. Changes in sales volumes, selling prices and costs of goods sold, and increases in interest rates could cause changes in our forecasted cash flows. Unfavorable changes in any of the factors described above, as well as a decline in our stock price, could result in a goodwill impairment charge in the future.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

*Hedging and Derivatives*

All derivative instruments are recorded as assets or liabilities on the balance sheet at fair value. Changes in the fair value of derivatives are either recorded in the income statement or other comprehensive income, as appropriate. The effective portion of the gain or loss on derivatives designated as cash flow hedges is included in other comprehensive income in the period that changes in fair value occur, and is reclassified to income in the same period that the hedged item affects income. Cash flows

from derivative instruments are recorded within operating, investing or financing activities in accordance with the classification of the underlying hedged transaction. Our policies allow the use of derivatives for risk management purposes and prohibit their use for speculation. Our policies also prohibit the use of any leveraged derivative instrument. Consistent with our policies, foreign currency derivative instruments are entered into with major financial institutions. At inception, we formally designate certain derivatives as cash flow hedges and establish how the effectiveness of these hedges will be assessed and measured. This process links the derivatives to the transactions they are hedging. See Note 11, "Derivative Financial Instruments," for disclosures about derivative instruments and hedging activities.

*Recently Adopted Accounting Pronouncements*

Effective January 1, 2026, we adopted ASU No. 2025-05, *Measurement of Credit Losses for Accounts Receivable and Contract Assets.* This ASU provides a practical expedient related to the estimation of expected credit losses for current accounts receivable and current contract assets that arise from transactions accounted for under Topic 606. Under the current guidance, when an entity estimates expected credit losses, it must consider available information that is relevant to its assessment of the collectability of cash flows, and the entity may need to adjust its historical losses to estimate expected credit losses if historical conditions differed from current conditions or from reasonable and supportable forecasts. Under this ASU, in developing reasonable and supportable forecasts as part of estimating expected credit losses, we elected the practical expedient that assumes that current conditions as of the balance sheet date do not change for the remaining life of the asset. Adoption of this ASU did not have a material effect on our financial position, results of operations or cash flows.

Effective January 1, 2025, we adopted ASU No. 2023-09, *Income Taxes: Improvements to Income Tax Disclosures.* This ASU pertains to disaggregation of income tax disclosures and enhances annual income tax disclosures to address investor requests for more information about the tax risks and opportunities present in an entity's worldwide operations. The two primary enhancements disaggregate existing income tax disclosures related to the effective tax rate reconciliation and income taxes paid, and requires entities to disclose a tabular reconciliation of expected tax and reported tax on income from continuing operations using both percentages and amounts, broken out into specific categories with certain reconciling items at or above 5% of the expected tax further broken out by nature and/or jurisdiction. Additionally, this ASU requires disclosure around income taxes paid (net of refunds received) broken out between federal, state, local and foreign, and income taxes paid (net of refunds received) to an individual jurisdiction when greater than 5% of total income taxes paid. Adoption of this ASU did not have a material effect on our financial position, results of operations or cash flows.

Effective January 1, 2025, we adopted ASU No. 2023-05, *Business Combinations: Joint Venture Formations.* This ASU is intended to address diversity in practice regarding accounting and provide decision-useful information related to contributions made to joint ventures and requires entities that qualify as either a joint venture or a corporate joint venture to apply a new basis of accounting upon the formation of the joint venture. Specifically, the ASU provides that a joint venture or a corporate joint venture must initially measure its assets and liabilities at fair value on the formation date. Adoption of this ASU did not have a material effect on our financial position, results of operations or cash flows.

Effective in the fourth quarter of 2024, we adopted ASU No. 2023-07, *Segment Reporting: Improvements to Reportable Segment Disclosures.* This ASU enhances segment reporting under Topic 280 by expanding the breadth and frequency of segment disclosures, and aims to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses that are regularly provided to the Chief Operating Decision Maker (CODM) and included in each reported measure of segment profit or loss. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. On an annual basis, this ASU requires us to disclose the CODM's title and position, as well as how the CODM uses each reported measure of segment profit or loss to assess performance and allocate resources to the segment. In accordance with this ASU, we have applied this guidance retrospectively for all periods presented in the financial statements in Note 4, "Segment Information". Adoption of this ASU did not have a material effect on our financial position, results of operations or cash flows.

*Recently Issued Accounting Pronouncements*

In November 2025, the FASB issued ASU No. 2025-09, *Hedge Accounting Improvements.* This ASU amends ASC Topic 815 to better align hedge accounting with the economics of an entity's risk management activities. The amendment permits aggregation of forecasted transactions with similar-risk exposures in cash flow hedges, expands eligibility for hedging certain non-financial forecasted transactions, and expands the application of hedge accounting for interest payments on choose-your-rate debt, including forecasted issuances. This ASU will be effective for fiscal years beginning after December 15, 2026, and

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

interim periods therein, with early adoption permitted. Adoption of this ASU is not expected to have a material effect on our financial position, results of operations or cash flows.

In September 2025, the FASB issued ASU No. 2025-06, *Targeted Improvements to the Accounting for Internal-Use Software.* This ASU amends certain aspects of the accounting for and disclosure of software costs under Topic 350 and removes all references to "development stages", modifying the criteria that must be met for entities to begin capitalizing software costs. This ASU also provides new guidance on how to evaluate whether the probable-to-complete recognition threshold has been met. This ASU will be effective for annual periods beginning after December 15, 2027, with early adoption permitted. Adoption of this ASU is not expected to have a material effect on our financial position, results of operations or cash flows.

In November 2024, the FASB issued ASU No. 2024-03, *Disaggregation of Income Statement Expenses.* This ASU requires disaggregated disclosure of income statement expenses for public business entities (PBEs) to address investor requests for more detailed information about the types of expenses in commonly presented expense captions. This ASU will require new tabular disclosures for the following expenses: (1) purchases of inventory, (2) employee compensation, (3) depreciation, (4) intangible asset amortization, and (5) depletion. Additionally, certain other expenses and gains or losses that must be disclosed under existing U.S. GAAP, and that are recorded in a relevant expense caption, must be presented in the same tabular disclosure. This ASU will be effective for annual periods beginning after December 15, 2026, with early adoption permitted. Adoption of this ASU is not expected to have a material effect on our financial position, results of operations or cash flows.

**Note 2.&nbsp;&nbsp;&nbsp;&nbsp;Restructuring Activities**

*Post-RH Divestiture Restructuring Plan*

During 2024, following the sale of our Respiratory Health business to SunMed Group Holdings in October 2023 (the "RH Divestiture"), we initiated restructuring activities aimed at aligning our organizational structure, our manufacturing and distribution activities, and our operational footprint with our remaining business ("the Plan"). In the first six months of 2025, the Plan was expanded to accommodate additional manufacturing and operational initiatives.

In the fourth quarter of 2025, the assessment of our organization performed in conjunction with the appointment of our new Chief Executive Officer in April 2025 was completed and the Plan was expanded to align our organizational structure with our business needs. As a result, we expect to incur up to $10.0 million of incremental expenses consisting primarily of employee severance and benefits. The initiatives associated with the expansion of the Plan are expected to run through 2026.

In the three months ended March 31, 2026, we incurred $1.8 million of costs related to the Plan, compared to $3.1 million in the three months ended March 31, 2025. These costs are included in "Cost of products sold" and "Selling and general expenses" in the accompanying condensed consolidated income statements. Since its initiation, we have incurred expenses of $43.1 million in connection with the Plan, including $31.5 million of cash expenses.

*Restructuring Liability*

Our liability for costs associated with our restructuring initiatives as of March 31, 2026 is summarized below (in millions):

---

| | |
|:---|:---|
| | **Restructuring Liability** |
| Balance, December 31, 2025 | $**7.2** |
| Restructuring and transformation costs, excluding non-cash charges | **1.4** |
| Payments and adjustments, net | **(7.6)** |
| Balance, March 31, 2026 | $**1.0** |

---

**Note 3.&nbsp;&nbsp;&nbsp;&nbsp;Business Acquisition**

***Nexus Medical***

On September 11, 2025, we entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Company, Nexus Merger Sub, LLC, a newly formed wholly owned subsidiary of the Company ("Merger Sub"), Nexus Medical, LLC, a Kansas limited liability company ("Nexus"), and Edward Kuklenski, as representative of Nexus' members. The transaction contemplated by the Merger Agreement (the "Merger") closed concurrently with the execution of the Merger Agreement. Pursuant to the Merger Agreement, Nexus merged with and into Merger Sub, with Nexus surviving the merger as a wholly owned subsidiary of the Company (the "Nexus Acquisition"). The total purchase price payable by the Company in the Merger was $27.0 million (subject to certain working capital and other adjustments), with up to an additional $20.0 million payable in contingent cash consideration based on the increase in net sales of certain Nexus product during the first three years following the Nexus Acquisition. The purchase price was funded by available cash on hand.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

Nexus is a leading manufacturer of anti-reflux needleless connectors. Its proprietary TKO<sup>®</sup> technology is designed to support safer, more consistent nutrition and medication delivery in high-acuity settings, including Neonatal and Pediatric Intensive Care Units (NICUs and PICUs). We expect the Nexus Acquisition will enhance our Specialty Nutrition Systems ("SNS") portfolio of products.

The accompanying condensed consolidated income statement includes $5.8 million of net sales from Nexus for the three months ended March 31, 2026. We incurred $0.9 million of costs in the three months ended March 31, 2026 in connection with the Nexus Acquisition, which are included in "Selling and general expenses" and "Other expense (income), net."

Under the acquisition method of accounting for business combinations, the purchase price paid is allocated to the underlying net assets in proportion to their respective fair values. Any excess of the purchase price over the estimated fair values is recorded as goodwill. Fair values of assets acquired and liabilities assumed are being determined using discounted cash flow analyses and the fair value of the contingent consideration is being estimated using a Monte Carlo simulation. Assumptions supporting the estimated fair values are based on facts and circumstances that existed on the valuation date. Estimated fair values may be revised during a measurement period, not to exceed 12 months from the date of acquisition, as valuations are finalized or additional information is obtained about facts and circumstances that existed on the valuation date. While the purchase price allocation may be revised for conditions known at the time of sale for a period of one year following the transaction, we do not expect any revisions. The purchase price allocation is shown in the table below (in millions):

---

| | |
|:---|:---|
| Current assets, net of liabilities assumed, excluding cash acquired | $7.9 |
| Property, plant & equipment | 2.2 |
| Identifiable intangible assets | 20.5 |
| Goodwill | 13.7 |
| Contingent consideration<sup>(a)</sup> | (16.3) |
| Total | $28.0 |

---

__________________________________________________

(a)The fair value of the contingent consideration was revalued as of March 31, 2026. See Note 6, "Fair Value Information" for further details.

The identifiable intangible assets relating to the Nexus Acquisition include the following (in millions, except years):

---

| | | |
|:---|:---|:---|
| | **Identifiable Intangible Asset Amount** | **Weighted Average Useful Lives (Years)** |
| Customer relationships | $15.3 | 11 |
| Patents | 3.4 | 9 |
| Trade names & other | 1.8 | 15 |
| Total | $20.5 |  |

---

The following unaudited pro forma financial information is presented in the table below for the three months ended March 31, 2025 as if the Nexus Acquisition had occurred on January 1, 2025 (in millions except per share amounts):

---

| | |
|:---|:---|
| | **Three Months Ended March 31, 2025** |
| Net sales | $171.5 |
| Net Income | 6.5 |
| Earnings Per Share: |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.14 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.14 |

---

The pro forma financial information has been adjusted to include the effects of the Nexus Acquisition, including acquisition-related costs, amortization of acquired intangibles and related tax effects. The pro-forma financial information is not necessarily indicative of the results of operations that would have been achieved.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

**Note 4.&nbsp;&nbsp;&nbsp;&nbsp;Segment Information**

We define our reportable segments based on the way our CODM manages the operations of the business for purposes of allocating resources and assessing performance. We conduct our business in two operating and reportable segments. Our reportable segments include the following:

*Specialty Nutrition Systems,* or SNS*,* is a portfolio of products including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Enteral feeding, which includes products such as our MIC-KEY enteral feeding tubes and Corpak patient feeding solutions; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Neonate solutions, which includes NeoMed neonatal and pediatric feeding solutions and Nexus' TKO<sup>®</sup> anti-reflux needleless connectors.

*Pain Management and Recovery,* or PM&R, is a portfolio of products including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Surgical pain and recovery products such as ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Radiofrequency Ablation ("RFA") solutions, which provide minimally invasive pain relief therapies, such as our COOLIEF, Trident and ESENTEC RFA products used to treat chronic pain conditions.

The CODM evaluates the performance of our two reportable segments and determines how to allocate resources based on Operating Income (Loss), and is regularly provided with segment revenues and expenses. The CODM receives and reviews total assets as presented in the Consolidated Balance Sheets, and does not evaluate asset information at the segment level. The significant expenses included in Operating Income, as regularly provided to the CODM, are as follows (in millions):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** |
| | **SNS** | **PM&R** | **Total** | **SNS** | **PM&R** | **Total** |
| **Net Sales** | $**124.0** | $**56.3** | $**180.3** | $101.1 | $56.2 | $157.3 |
| Reconciliation of consolidated net sales: |  |  | **—** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate and other<sup>(a)</sup> |  |  | **1.9** |  |  | 10.2 |
| Total consolidated net sales |  |  | $**182.2** |  |  | $167.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold | **(48.0)** | **(21.7)** |  | (35.2) | (20.7) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Distribution | **(7.1)** | **(3.2)** |  | (6.3) | (2.7) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses | **(3.7)** | **(1.3)** |  | (4.1) | (1.1) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Advertising, promotion and selling expenses | **(15.1)** | **(15.9)** |  | (11.8) | (14.9) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;General expenses | **(20.8)** | **(12.3)** |  | (17.5) | (12.7) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization expense | **(6.1)** | **(3.7)** |  | (5.0) | (3.9) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other segment items | **(0.1)** | **—** |  | (0.1) |  |  |
| Reportable segment operating income (loss) | $**23.1** | $**(1.8)** | $**21.3** | $21.1 | $0.2 | $21.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate and other |  |  | **(12.4)** |  |  | (11.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net |  |  | **(1.3)** |  |  | (0.6) |
| Income before income taxes |  |  | $**7.6** |  |  | $9.7 |

---

__________________________________________________

(a)Corporate and other net sales includes revenue from our IV infusion oncology pumps.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

**Note 5.&nbsp;&nbsp;&nbsp;&nbsp;Supplemental Balance Sheet Information**

*Accounts Receivable*

Accounts receivable consist of the following (in millions):

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| Accounts receivable | $**106.3** | $108.0 |
| Income tax receivable | **0.1** | 0.1 |
| Allowances and doubtful accounts: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Doubtful accounts | **(3.1)** | (4.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales discounts | **(0.3)** | (0.3) |
| Total Accounts receivable, net of allowances | $**103.0** | $103.8 |

---

Losses on receivables are estimated based on known troubled accounts and historical experience. In developing forecasts as part of estimating expected credit losses, we assume that current conditions as of the balance sheet date do not change for the life of the asset. Receivables are considered impaired and written off when it is probable that payments due will not be collected. Bad debt expense was a net benefit of $0.4 million for the three months ended March 31, 2026, compared to $0.1 million for the three months ended March 31, 2025.

*Inventories*

Inventories at the lower of cost (determined on the FIFO method) or net realizable value consists of the following (in millions):

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| Raw materials | $**34.1** | $34.7 |
| Work in process | **25.0** | 25.2 |
| Finished goods | **78.2** | 84.0 |
| Supplies and other | **4.0** | 4.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Inventories | $**141.3** | $148.0 |

---

We incurred $3.3 million of expense for inventory write-offs and obsolescence in the three months ended March 31, 2026, compared to $1.7 million in the three months ended March 31, 2025.

*Property, Plant and Equipment*

Property, plant and equipment consists of the following (in millions):

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| Land | $**1.3** | $1.3 |
| Buildings and leasehold improvements | **39.9** | 40.1 |
| Machinery and equipment | **201.9** | 199.1 |
| Construction in progress | **25.4** | 25.0 |
|  | **268.5** | 265.5 |
| Less accumulated depreciation | **(157.3)** | (152.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Property, Plant and Equipment, net | $**111.2** | $113.4 |

---

Depreciation expense was $5.6 million for the three months ended March 31, 2026, compared to $4.5 million for the three months ended March 31, 2025.

*Goodwill and Intangible Assets*

We test goodwill for impairment annually or more frequently whenever events or circumstances more likely than not indicate that the fair value of our reporting units may be below their respective carrying amounts.

In our most recent goodwill impairment test on July 1, 2025, we determined that the fair value of our reporting units equaled or exceeded the net carrying amount of our reporting units.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

The changes in the carrying amount of goodwill are as follows (in millions):

---

| | | | |
|:---|:---|:---|:---|
| | **SNS** | **PM&R** | **Total** |
| Balance, December 31, 2025 | $341.3 | $53.6 | $394.9 |
| Currency translation adjustment |  | (0.9) | (0.9) |
| Balance, March 31, 2026 | $**341.3** | $**52.7** | $**394.0** |

---

Intangible assets subject to amortization consist of the following (in millions):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| | **Gross<br>Carrying<br>Amount** | **Accumulated<br>Amortization** | **Net Carrying Amount** | **Gross<br>Carrying<br>Amount** | **Accumulated<br>Amortization** | **Net Carrying Amount** |
| Trademarks | $**41.9** | $**(31.1)** | $**10.8** | $41.9 | $(30.8) | $11.1 |
| Patents and acquired technologies | **251.8** | **(193.9)** | **57.9** | 251.9 | (191.5) | 60.4 |
| Other | **95.5** | **(49.5)** | **46.0** | 94.1 | (47.8) | 46.3 |
| Total | $**389.2** | $**(274.5)** | $**114.7** | $387.9 | $(270.1) | $117.8 |

---

Amortization expense for intangible assets is included in "Cost of products sold" and "Selling and general expenses" and was $4.6 million for the three months ended March 31, 2026, compared to $5.1 million for the three months ended March 31, 2025.

Amortization expense for the remainder of 2026, the following four years and thereafter is estimated as follows (in millions):

---

| | |
|:---|:---|
| | **Amount** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Remainder of 2026 | $14.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2027 | 17.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2028 | 16.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2029 | 15.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2030 | 12.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thereafter | 39.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $114.7 |

---

*Accrued Expenses*

Accrued expenses consist of the following (in millions):

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| Accrued rebates and customer incentives | $**11.0** | $13.1 |
| Accrued salaries and wages | **21.7** | 37.0 |
| Accrued taxes and other | **6.6** | 16.9 |
| Other<sup>(a)</sup> | **18.3** | 24.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Accrued Expenses | $**57.6** | $91.3 |

---

__________________________________________________

(a)Other includes $7.5 million of contingent consideration associated with the acquisition of Nexus. See Note 3, "Business Acquisition" for further information.

*Other Long-Term Liabilities*

Other long-term liabilities consist of the following (in millions):

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| Accrued compensation and benefits | $**4.1** | $4.0 |
| Other<sup>(a)</sup> | **10.0** | 9.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Other Long-Term Liabilities | $**14.1** | $13.5 |

---

__________________________________________________

(a)Other includes $9.8 million and $9.3 million of contingent consideration associated with the acquisition of Nexus as of March 31, 2026 and December 31, 2025, respectively . See Note 3, "Business Acquisition" for further information.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

**Note 6.&nbsp;&nbsp;&nbsp;&nbsp;Fair Value Information**

The following fair value information is based on a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels in the hierarchy used to measure fair value are:

Level 1: Unadjusted quoted prices in active markets accessible at the reporting date for identical assets and liabilities.

Level 2: Quoted prices for similar assets or liabilities in active markets. Quoted prices for identical or similar assets and liabilities in markets that are not considered active or financial instruments for which all significant inputs are observable, either directly or indirectly.

Level 3: Prices or valuations that require inputs that are significant to the valuation and are unobservable.

A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The following table includes the fair value of our financial instruments for which disclosure of fair value is required (in millions):

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** |
| |<br>**Fair Value<br>Hierarchy<br>Level** | **Carrying<br>Amount** | **Estimated<br>Fair<br>Value** | **Carrying<br>Amount** | **Estimated<br>Fair<br>Value** |
| **Assets** | | | | | |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | 1 | $**65.6** | $**65.6** | $89.8 | $89.8 |
| **Liabilities** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revolving Credit Facility | 2 | $**—** | $**—** | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term Loan Facility | 2 | **98.2** | **98.2** | 100.5 | 100.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contingent consideration related to acquisition | 3 | **17.3** | **17.3** | 16.8 | 16.8 |

---

Cash equivalents are recorded at cost, which approximates fair value due to their short-term nature. The fair value of amounts borrowed under our Revolving Credit Facility and Term Loan Facility approximates carrying value because borrowings are subject to a variable rate as described in Note 7, "Debt". The fair value amount of the contingent consideration is remeasured on an ongoing basis using a probability-weighted discounted cash flow model. See further discussion of the Nexus acquisition in Note 3, "Business Acquisition".

**Note 7. &nbsp;&nbsp;&nbsp;&nbsp;Debt**

As of March 31, 2026 and December 31, 2025, our respective debt balances were as follows (in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Weighted-Average Interest Rate** | **Maturity** | **March 31, 2026** | **December 31, 2025** |
| Revolving Credit Facility | 5.94% | 2027 | $**—** | $— |
| Term Loan Facility | 5.28% | 2027 | **98.4** | 100.8 |
|  |  |  | **98.4** | 100.8 |
| Unamortized debt issuance costs |  |  | **(0.2)** | (0.3) |
| Current portion of long-term debt |  |  | **(10.9)** | (10.2) |
| Total Long-Term Debt, net |  |  | $**87.3** | $90.3 |

---

On June 24, 2022, we entered into a credit agreement (the "Credit Agreement") with certain lenders which established credit facilities in an aggregate principal amount of $500.0 million, consisting of a five-year senior secured term loan of $125.0 million (the "Term Loan Facility") and a five-year senior secured revolving credit facility allowing borrowings of up to $375.0 million, with a letter of credit sub-facility in an amount of $75.0 million (the "Revolving Credit Facility"). All obligations under the Credit Agreement and certain hedging agreements and cash management arrangements thereunder are: (i) guaranteed by each of the Company's direct and indirect, existing and future, material wholly owned domestic subsidiaries ("Guarantors") and (ii) secured by a first priority lien on substantially all the assets of the Company and the Guarantors. The Credit Agreement contains an accordion feature that allows us to incur incremental term loans under the Term Loan Facility or under new term loan facilities or to increase the amount of the commitments under the Revolving Credit Facility, including through the establishment of one or more tranches under the Revolving Credit Facility. The Credit Agreement will mature on June 24, 2027.

Borrowings under the Term Loan Facility and Revolving Credit Facility bear interest at our option at either: (i) an adjusted term secured overnight financing rate ("SOFR"), plus a margin ranging between 1.50% to 2.00% per annum, depending on our

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

consolidated total leverage ratio; (ii) an adjusted daily simple SOFR rate, plus a margin ranging between 1.50% to 2.00% per annum, depending on our consolidated total leverage ratio; or (iii) a base rate (calculated as the greatest of (a) the prime rate, (b) the NYFRB rate (being the greater of the federal funds effective rate or the overnight bank funding rate) plus 0.50%, and (c) the one month adjusted term SOFR rate plus 1.00%), plus a margin ranging between 0.50% to 1.00% per annum, depending on our consolidated total leverage ratio. The unused portion of the Revolving Credit Facility will be subject to a commitment fee ranging between 0.20% to 0.25% per annum, depending on our consolidated total leverage ratio. Unamortized debt discount and issuance costs are being amortized to interest expense over the life of the Term Loan Facility using the interest method, resulting in an effective interest rate of 5.5% as of March 31, 2026.

The Credit Agreement requires compliance with certain customary operational and financial covenants. As of March 31, 2026, we were in compliance with these covenants. In addition, the Credit Agreement contains certain other customary limitations on our ability to, among other things: incur additional indebtedness; pay dividends on or repurchase or redeem our capital stock; make loans, investments and acquisitions; sell, transfer or otherwise dispose of assets; guarantee other obligations; create or grant liens; and enter into certain types of transactions with affiliates. Notwithstanding such limitations, the Credit Agreement allows us to pay dividends, repurchase stock and make investments up to an "Available Amount," as defined in the Credit Agreement, provided no event of default has occurred and certain financial ratios have been achieved on a pro forma basis. We are permitted to prepay all or a portion of the Term Loan Facility and the Revolving Credit Facility at any time without premium or penalty.

*Debt Payments*

The Credit Agreement requires quarterly principal installment payments on the Term Loan Facility of 10% of the total principal borrowed for the first eight quarters following funding and then quarterly installment payments of 20% of the total principal borrowed, at which time the remaining unpaid principal amount of the Term Loan Facility is due and payable by the Company upon the maturity date of June 24, 2027. The current portion of the Term Loan Facility is $10.9 million. Interest is payable quarterly. We have the right to voluntarily prepay the Term Loan Facility in accordance with the terms of the Credit Agreement. Interest is payable at the same rates set forth above for the Revolving Credit Facility.

During the three months ended March 31, 2026, we repaid $2.3 million of the Term Loan Facility. As of March 31, 2026, we had letters of credit outstanding of $3.6 million.

As of March 31, 2026, the aggregate amounts of long-term debt that will mature during each of the next four years are as follows (in millions):

---

| | |
|:---|:---|
| | **Amount** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Remainder of 2026 | $7.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2027 | 90.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2028 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2029 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2030 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $98.4 |

---

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

**Note 8.&nbsp;&nbsp;&nbsp;&nbsp;Accumulated Other Comprehensive Loss**

The changes in the components of Accumulated Other Comprehensive Loss ("AOCL"), net of tax, are as follows (in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Unrealized Currency<br>Translation** | **Cash Flow<br>Hedges** | **Defined Benefit<br>Plans** | **Accumulated<br>Other<br>Comprehensive Loss** |
| Balance, December 31, 2025 | $(31.9) | $(0.2) | $0.1 | $(32.0) |
| Other comprehensive (loss) income | **(5.5)** | **1.5** | **—** | **(4.0)** |
| Balance, March 31, 2026 | $**(37.4)** | $**1.3** | $**0.1** | $**(36.0)** |

---

The net changes in the components of AOCL, including the tax effect, are as follows (in millions):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Unrealized currency translation | $**(5.5)** | $2.3 |
| Defined benefit pension plans, net of tax | **—** | 0.1 |
| Cash flow hedges, net of tax | **1.5** | (0.1) |
| Change in AOCL | $**(4.0)** | $2.3 |

---

**Note 9.** &nbsp;&nbsp;&nbsp;&nbsp;**Stock-Based Compensation**

Stock-based compensation expense is included in "Cost of products sold," "Research and development," and "Selling and general expenses." Stock-based compensation expense for the three months ended March 31, 2026 and 2025 is shown in the table below (in millions):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Stock options | $**0.2** | $— |
| Time-based restricted share units | **1.3** | 3.1 |
| Performance-based restricted share units | **2.2** | 0.7 |
| Employee stock purchase plan | **—** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stock-based compensation | $**3.7** | $3.8 |

---

**Note 10.&nbsp;&nbsp;&nbsp;&nbsp;Commitments and Contingencies**

*Legal Matters*

We are subject to various legal proceedings, claims and governmental inspections, audits or investigations pertaining to issues such as contract disputes, product liability, tax matters, patents and trademarks, advertising, governmental regulations, employment and other matters. Under the terms of the distribution agreement we entered into with Kimberly-Clark Corporation ("Kimberly-Clark") prior to our 2014 spin-off from Kimberly-Clark, legal proceedings, claims and other liabilities that are primarily related to our business are our responsibility and we are obligated to indemnify and hold Kimberly-Clark harmless for such matters. For the three months ended March 31, 2026 and 2025, we incurred no costs with respect to such indemnification matters.

*Government Investigation*

On July 6, 2021, we entered into a Deferred Prosecution Agreement ("DPA") with the United States Department of Justice ("DOJ") that resolved their criminal investigation related to the design, manufacture, testing, sale and promotion of MicroCool surgical gowns produced by the Company. Pursuant to the terms of the DPA, in July 2021 the Company made a payment of $22.2 million. The DPA term expired on July 7, 2024 and in January 2025, the United States District Court for the Northern District of Texas dismissed the DOJ's case against the Company.

*Patent Litigation*

We operate in an industry characterized by extensive patent litigation. Competitors may claim that our products infringe upon their intellectual property. Resolution of patent litigation or other intellectual property claims is typically time consuming and costly and can result in significant damage awards and injunctions that could prevent the manufacture and sale of the affected products or require us to make significant royalty payments in order to continue selling the affected products.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

At any given time, we may be involved as either a plaintiff or a defendant in a number of patent infringement actions, the outcomes of which may not be known for prolonged periods of time.

*General*

While we maintain general and professional liability, product liability and other insurance, our insurance policies may not cover all of these matters and may not fully cover liabilities arising out of these matters. In addition, we may be obligated to indemnify our directors and officers against these matters.

We record provisions in the consolidated financial statements for pending litigation when we determine that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. For any matters that are reasonably possible to result in loss and for which no possible loss or range of loss is disclosed in this Form 10-Q, management has determined that it is unable to estimate the possible loss or range of loss because, in each case, at least the following facts applied: (a) the matter is at an early stage of the proceedings; (b) the damages are indeterminate, unspecified or determined to be immaterial; and (c) significant factual issues have yet to be resolved. At present, although the results of litigation and claims cannot be predicted with certainty, we believe that the ultimate resolution of any pending legal proceeding to which we are a party will not have a material adverse effect on our business, financial condition, results of operations or liquidity.

*Environmental Compliance*

We are subject to federal, state and local environmental protection laws and regulations with respect to our business operations. We believe we are operating in compliance with, or are taking action aimed at ensuring compliance with, these laws and regulations. None of our compliance obligations with environmental protection laws and regulations, individually or in the aggregate, is expected to have a material adverse effect on our business, financial condition, results of operations or liquidity.

**Note 11. &nbsp;&nbsp;&nbsp;&nbsp;Derivative Financial Instruments**

We enter into derivative instruments to hedge a portion of forecasted cash flows denominated in Mexican pesos. The derivative instruments used to manage these exposures are designated and qualify as cash flow hedges. The derivative liability for foreign exchange contracts was $1.2 million as of March 31, 2026 and is included in the condensed consolidated balance sheet in accrued expenses. We did not have a derivative asset or liability for foreign exchange contracts as of December 31, 2025.

The effective portion of the gain or loss on a derivative instrument is initially recorded in AOCI, net of related income taxes, and recognized in earnings in the same period that the hedged exposure affects earnings. The gain recognized in earnings was not material in the three months ended March 31, 2026. The loss recognized in earnings was not material in the three months ended March 31, 2025. As of March 31, 2026, the aggregate notional values of outstanding foreign currency swap contracts designated as cash flow hedges were $43.2 million.

During the year ended December 31, 2025, we entered into a pay-fixed, receive-variable interest rate swap with a notional amount of $65 million, intended to fix the one-month SOFR rate on that portion of our Term Loan Facility. The variable portion of the interest rate swap and the interest rate on our Term Loan Facility is tied to the one-month SOFR rate. Monthly, the interest rate swap agreement is settled with the counterparty in conjunction with the one-month SOFR reset on our Term Loan Facility. The gain recognized in earnings was not material in the three months ended March 31, 2026. The derivative asset for the interest rate swap was $0.2 million as of March 31, 2026 and is included in the condensed consolidated balance sheet in other assets.

**Note 12.&nbsp;&nbsp;&nbsp;&nbsp;Earnings Per Share ("EPS")** 

Basic EPS is calculated by dividing net income by the weighted average number of common shares outstanding during each period. Diluted earnings per share is calculated by dividing net income by the number of common shares outstanding and the effect of all dilutive common stock equivalents outstanding during each period, as determined using the treasury stock method.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

The calculation of basic and diluted earnings per share for the three months ended March 31, 2026 and 2025 is set forth in the following table (in millions, except per share amounts):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Net Income | $**5.1** | $6.6 |
| Weighted Average Shares Outstanding: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic weighted average shares outstanding | **46.5** | 46.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dilutive effect of stock options and restricted share unit awards | **1.0** | 0.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted weighted average shares outstanding | **47.5** | 46.8 |
| Earnings Per Share |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $**0.11** | $0.14 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $**0.11** | $0.14 |

---

Restricted share units ("RSUs") contain provisions allowing for the equivalent of any dividends paid on common stock during the restricted period to be reinvested into additional RSUs at the then fair market value of the common stock on the date the dividends are paid. Such awards are to be included in the EPS calculation under the two-class method. Currently, we do not anticipate any cash dividends for the foreseeable future and our outstanding RSU awards are not material in comparison to our weighted average shares outstanding. Accordingly, all EPS amounts reflect shares as if they were fully vested and the disclosures associated with the two-class method are not presented herein.

For the three months ended March 31, 2026, 1.2 million of potentially dilutive stock options and RSU awards were excluded from the computation of earnings per share as their effect would have been anti-dilutive.

**Note 13.&nbsp;&nbsp;&nbsp;&nbsp; Revenue**

Sales revenue is recognized when control of the products transfers to the customer, in an amount that represents the consideration that we expect to be entitled to receive in exchange for our products.

We provide a portfolio of innovative product offerings within our SNS and PM&R segments to improve patient outcomes and reduce the cost of care. Our management evaluates net sales disaggregated by product category within these two reportable segments as follows (in millions):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Specialty Nutrition Systems: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enteral feeding | $**84.6** | $74.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neonate solutions | **39.4** | 26.6 |
| Total Specialty Nutrition Systems | **124.0** | 101.1 |
| Pain Management and Recovery: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Surgical pain and recovery | **21.8** | 24.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Radiofrequency ablation | **34.5** | 31.7 |
| Total Pain Management and Recovery | **56.3** | 56.2 |
| Corporate and Other | **1.9** | 10.2 |
| Total Net Sales | $**182.2** | $167.5 |

---

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

Liabilities for estimated returns, rebates and incentives are presented in the table below (in millions):

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| Accrued rebates | $**1.0** | $3.3 |
| Accrued customer incentives | **10.0** | 9.8 |
| Accrued rebates and customer incentives | **11.0** | 13.1 |
| Accrued sales returns<sup>(a)</sup> | **0.1** | 0.1 |
| Total estimated liabilities | $**11.1** | $13.2 |

---

__________________________________________________

(a)Accrued sales returns are included in "Other" in the accrued expenses table in Note 5, "Supplemental Balance Sheet Information".

Due to the nature of our business, we receive purchase orders for products under supply agreements which are normally fulfilled within three to four weeks. Our performance obligations under purchase orders are satisfied and revenue is recognized at a point in time, which is upon shipment or upon delivery of our products, depending on shipping terms. Accordingly, we normally do not have transactions that give rise to material unfulfilled performance obligations.

**Note 14.&nbsp;&nbsp;&nbsp;&nbsp; Subsequent Event**

*Pending Merger*

On April 13, 2026, we entered into an Agreement and Plan of Merger (the "Merger Agreement") with A-AV Holdco I, Inc. ("Parent") and A-AV MergerSub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub will merge with and into Avanos (the "Merger"), with Avanos surviving as a wholly owned subsidiary of Parent. Parent and Merger Sub are affiliates of American Industrial Partners ("AIP"), an operationally oriented industrials investor.

At the effective time of the Merger, each issued and outstanding share of our common stock (other than certain excluded shares and shares held by stockholders who properly exercise appraisal rights) will be cancelled and converted into the right to receive $25.00 per share in cash, without interest.

In addition, at or immediately prior to the effective time, our outstanding equity awards, including stock options and restricted stock units, will be cancelled and converted into the right to receive cash payments based on the Merger consideration, subject to the terms of the Merger Agreement.

The consummation of the Merger is subject to customary closing conditions, including adoption and approval of the Merger Agreement by the affirmative vote of the holders of a majority of the outstanding shares entitled to vote thereon and receipt of required regulatory approvals, including under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The Merger is not subject to a financing condition.

The Merger Agreement contains customary representations, warranties and covenants, including covenants relating to our conduct of its business between the signing of the Merger Agreement and the completion of the Merger.

The Merger Agreement also contains customary termination provisions, including the right of either party to terminate the agreement under specified circumstances, including if the Merger is not consummated by January 13, 2027; if required stockholder approval is not obtained; or if certain closing conditions are not satisfied. In addition, upon termination of the Merger Agreement under specified circumstances, including if we terminate the Merger Agreement to enter into an alternative acquisition agreement with respect to a Superior Proposal (as defined in the Merger Agreement), we would be required to pay Parent a termination fee of $37.5 million.

If the Merger Agreement is consummated, we will become a privately held company and our common stock will be delisted from the New York Stock Exchange and deregistered under the Securities Exchange Act of 1934, as amended. No adjustments have been made to the accompanying financial statements related to the Merger transaction.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

**Item 2.&nbsp;&nbsp;&nbsp;&nbsp;Management's Discussion and Analysis of Financial Condition and Results of Operations**

**Introduction**

Avanos is a medical technology company focused on delivering clinically superior medical device solutions that help patients get back to the things that matter. We are committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. We develop, manufacture and market our recognized brands globally and hold leading market positions in multiple categories across our portfolio.

This Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to provide investors with an understanding of our recent performance, and should be read in conjunction with the condensed consolidated financial statements contained in Item 1, "Financial Statements" in this Form 10-Q and our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2025 (the "Form 10-K"). This MD&A contains forward-looking statements. Refer to "Information Concerning Forward-Looking Statements" at the beginning of this Form 10-Q for an explanation of these types of statements.

The following will be discussed and analyzed:

• Pending Merger;

• Restructuring Activities;

• Business Acquisition;

• Risks Related to Tariffs;

• Results of Operations and Related Information;

• Liquidity and Capital Resources; and

• Critical Accounting Policies and Use of Estimates.

**Pending Merger**

On April 13, 2026, we entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Company, A-AV Holdco I, Inc., a Delaware corporation ("Parent"), and A-AV MergerSub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Upon the terms and conditions set forth in the Merger Agreement, Merger Subsidiary will be merged with and into Avanos (the "Merger"), with Avanos surviving the Merger as a wholly-owned subsidiary of Parent. Parent and Merger Sub are affiliates of American Industrial Partners ("AIP"), an operationally oriented industrials investor.

At the effective time of the Merger, each issued and outstanding share of our common stock (other than certain excluded shares and shares held by stockholders who properly exercise appraisal rights) will be cancelled and converted into the right to receive $25.00 per share in cash, without interest. In addition, at or immediately prior to the effective time, our outstanding equity awards, including stock options and restricted stock units, will be cancelled and converted into the right to receive cash payments based on the Merger consideration, subject to the terms of the Merger Agreement.

A copy of the Merger Agreement is attached as Exhibit 2.1 to our Current Report on Form 8-K dated April 14, 2026. The foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger Agreement.

See Note 14, "Subsequent Event" in Item 1 of this Form 10-Q for further details regarding the pending Merger.

**Restructuring Activities**

*Post-RH Divestiture Plan*

During 2024, following the sale of our Respiratory Health business to SunMed Group Holdings in October 2023 (the "RH Divestiture"), we initiated restructuring activities aimed at aligning our organizational structure, our manufacturing and distribution activities, and our operational footprint with our remaining business (the "Plan"). In the first six months of 2025, the Plan was expanded to accommodate additional manufacturing and operational initiatives.

In the fourth quarter of 2025, the assessment of our organization performed in conjunction with the appointment of our new Chief Executive Officer in April 2025 was completed and the Plan was expanded to align our organizational structure with our business needs. As a result, we expect to incur up to $10.0 million of incremental expenses consisting primarily of employee

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

severance and benefits. We anticipate annualized savings from these initiatives to be between $15.0 million and $20.0 million. The initiatives associated with the expansion of the Plan are expected to run through 2026.

In the three months ended March 31, 2026, we incurred $1.8 million of costs related to the Plan, compared to $3.1 million in the three months ended March 31, 2025. These costs were included in "Cost of products sold" and "Selling and general expenses" in the accompanying condensed consolidated income statements.

**Business Acquisition**

On September 11, 2025 we entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Company, Nexus Merger Sub, LLC, a newly formed wholly owned subsidiary of the Company ("Merger Sub"), Nexus Medical, LLC, a Kansas limited liability company ("Nexus"), and Edward Kuklenski, as representative of Nexus' members. The transaction contemplated by the Merger Agreement (the "Merger") closed concurrently with the execution of the Merger Agreement. Pursuant to the Merger Agreement, Nexus merged with and into Merger Sub, with Nexus surviving the merger as a wholly owned subsidiary of the Company (the "Nexus Acquisition"). The total purchase price payable by the Company in the Merger was $27.0 million (subject to certain working capital and other adjustments), with up to an additional $20.0 million payable in contingent cash consideration based on the increase in net sales of certain Nexus products during the first three years following the acquisition. The purchase price was funded by available cash on hand.

Nexus is a leading manufacturer of anti-reflux needleless connectors. Its proprietary TKO<sup>®</sup> anti-reflux needleless connector technology, designed to support safer, more consistent nutrition and medication delivery in high-acuity settings, including Neonatal and Pediatric Intensive Care Units (NICUs and PICUs). We expect the acquisition of Nexus will enhance our Specialty Nutrition Systems ("SNS") portfolio of products.

See Note 3, "Business Acquisition" in Item 1 of this Form 10-Q for further details regarding the Nexus acquisition.

**Risks Related to Tariffs**

The tariffs imposed to date, and the imposition of new and increased U.S. tariffs and retaliatory trade measures by other countries pose significant risks to our global operations, particularly given our reliance on manufacturing facilities in Mexico and Canada, and on raw materials and components sourced from foreign suppliers, including suppliers in China and Mexico. In addition, we distribute and sell our products globally. The tariffs imposed to date have increased the cost of the products and components we import and may disrupt our established supply chains. Additional tariffs have been threatened by the U.S. administration. We have taken action to mitigate the impact of tariffs, including through cost containment measures, pricing actions where appropriate, supply chain adjustments and reliance on international agreements that allow for reduced or duty-free importation of products. However, tariff rates continue to fluctuate and the rates that may ultimately be in effect for the near and long term are uncertain. Our inability to offset increased costs of, or a drop in demand for, our products as a result of tariffs could materially negatively affect our financial performance. See Part I, Item 1A, "Risk Factors" in our most recent Form 10-K for the year ended December 31, 2025 for a more detailed description of the risks related to the imposition of new and retaliatory tariffs.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

**Results of Operations and Related Information**

*Use of Non-GAAP Measures*

In this section, we present "Adjusted operating income," which is a profitability measure that is not calculated in accordance with accounting principles generally accepted in the United States ("GAAP") and is therefore referred to as a non-GAAP financial measure. We provide this non-GAAP measure because we use it to measure our operational performance and provide greater insight into our ongoing business operations. This measure is not intended to be, and should not be, considered separately from, or an alternative to, the most directly comparable GAAP financial measures. A reconciliation of the non-GAAP measure to the most directly comparable GAAP financial measures is provided below under "Adjusted operating profit."

*Net Sales*

Our net sales are summarized in the following table for the three months ended March 31, 2026 and 2025 (in millions):

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | | **Three Months Ended March 31,** | **Three Months Ended March 31,** | |
| | | | **2026** | **2025** |<br>**Change** |
| Specialty Nutrition Systems: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enteral feeding |  |  | $**84.6** | $74.5 | 13.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neonate solutions |  |  | **39.4** | 26.6 | 48.1% |
| Total Specialty Nutrition Systems |  |  | **124.0** | 101.1 | 22.7% |
| Pain Management and Recovery: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Surgical pain and recovery |  |  | **21.8** | 24.5 | (11.0)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Radiofrequency ablation |  |  | **34.5** | 31.7 | 8.8% |
| Total Pain Management and Recovery |  |  | **56.3** | 56.2 | 0.2% |
| Segment Net Sales |  |  | **180.3** | 157.3 | 14.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate and Other |  |  | **1.9** | 10.2 | (81.4)% |
| Total Net Sales |  |  | $**182.2** | $167.5 | 8.8% |
| **Net Sales - Percentage Change:** | **Total** | **Volume** | **Pricing/Mix** | **Currency** | **Other**<sup>(a)</sup> |
| Specialty Nutrition Systems | 22.7% | 19.0% | 1.4% | 2.8% | (0.5)% |
| Pain Management and Recovery | 0.2% | 3.2% | 0.1% | 1.0% | (4.1)% |
| Corporate and Other | (81.4)% | (81.4)% | —% | —% | —% |

---

___________________________________________________________________________

(a)Other includes the effects of our withdrawal from certain revenue streams that did not meet our return criteria and rounding.

**Segment and Product Category Descriptions**

*Specialty Nutrition Systems,* or SNS, is a portfolio of products including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Enteral feeding, which includes products such as our MIC-KEY enteral feeding tubes and Corpak patient feeding solutions; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Neonate solutions, which includes NeoMed neonatal and pediatric feeding solutions and Nexus' TKO<sup>®</sup> anti-reflux needleless connectors.

*Pain Management and Recovery,* or PM&R, is a portfolio of products including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Surgical pain and recovery products such as ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Radiofrequency Ablation ("RFA") solutions, which provide minimally invasive pain relief therapies, such as our COOLIEF pain therapy and our Trident and ESENTEC RFA products used to treat chronic pain conditions.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

**Net Sales by Segment - First Three Months of 2026 Compared to the First Three Months of 2025**

*Specialty Nutrition Systems*

For the three months ended March 31, 2026, SNS net sales were $124.0 million, an increase of 22.7% compared to the prior year period. Volume growth was 19.0%, primarily driven by continued strong demand across both our enteral feeding and neonate solutions.

*Pain Management and Recovery*

For the three months ended March 31, 2026, PM&R net sales were $56.3 million. Overall net sales growth was relatively flat compared to the prior year period. RFA solutions net sales grew 8.8%, while surgical pain and recovery net sales decreased by 11.0%, primarily driven by lower volume.

*Net Sales by Geographic Region*

Net sales by region is presented in the table below (in millions):

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | |
| | **2026** | **2025** |<br>**% Change** |
| North America | $**137.1** | $130.8 | 4.8% |
| Europe, Middle East and Africa | **30.6** | 23.7 | 29.1 |
| Asia Pacific and Latin America | **14.5** | 13.0 | 11.5 |
| Total net sales | $**182.2** | $167.5 | 8.8% |

---

**Cost of Products Sold (in millions):**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Specialty Nutrition Systems | $**57.4** | $43.4 |
| Pain Management and Recovery | **26.5** | 24.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Segment Cost of Products Sold<sup>(a)</sup> | **83.9** | 68.3 |
| Corporate and Other | **4.1** | 9.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Cost of Products Sold | $**88.0** | $77.7 |

---

__________________________________________________

(a)&nbsp;&nbsp;&nbsp;&nbsp;Segment Cost of Products Sold includes the "Cost of goods sold" and "Distribution" line items in "Segment Information" in Note 4 to the condensed consolidated financial statements, $4.3 million of depreciation and amortization expense in the three months ended March 31, 2026, and $3.4 million of depreciation and amortization expense in the three months ended March 31, 2025.

For the three months ended March 31, 2026, cost of products sold increased compared to the prior year period, primarily due to increased tariffs along with an increase in segment net sales.

**Research and Development (in millions):**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Specialty Nutrition Systems | $**3.9** | $4.2 |
| Pain Management and Recovery | **1.3** | 1.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Segment Research and Development | **5.2** | 5.4 |
| Corporate and Other | **—** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Research and Development | $**5.2** | $5.4 |

---

__________________________________________________

(a)&nbsp;&nbsp;&nbsp;&nbsp;Segment Research and Development includes $0.2 million of depreciation and amortization expense in each of the three months ended March 31, 2026 and 2025.

Research and development consists primarily of compensation for personnel and expenses for product trial costs, outside laboratory and license fees, the cost of laboratory equipment and facilities and asset write-offs for equipment associated with unsuccessful product launches.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

**Selling and General Expenses (in millions):**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Specialty Nutrition Systems | $**39.5** | $32.3 |
| Pain Management and Recovery | **30.2** | 29.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Segment Selling and General Expenses | **69.7** | 62.2 |
| Corporate and Other | **8.0** | 13.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Selling and General Expenses | $**77.7** | $75.7 |

---

__________________________________________________

(a)&nbsp;&nbsp;&nbsp;&nbsp;Segment Selling and General Expenses includes the "Advertising, promotion and selling expenses" and "General expenses" line items in "Segment Information" in Note 4 to the condensed consolidated financial statements and $5.6 million of depreciation and amortization expense in the three months ended March 31, 2026, and $5.3 million of depreciation and amortization expenses in the three months ended March 31, 2025.

In the three months ended March 31, 2026, selling and general expenses increased compared to the prior year period, driven by higher selling costs partially offset by savings realized from our restructuring activities.

**Other Expense (Income), net (in millions):**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Specialty Nutrition Systems | $**0.1** | $0.1 |
| Pain Management and Recovery | **—** | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Segment Other Expense, net | **0.1** | 0.2 |
| Corporate and Other | **2.3** | (1.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Other Expense (Income), net | $**2.4** | $(1.6) |

---

Other income and expense, net was an expense of $2.4 million for the three months ended March 31, 2026, compared to other income, net of $1.6 million in the three months ended March 31, 2025. Other income in the three months ended March 31, 2025 includes a recovery of $1.4 million related to a customer claim in 2023.

**Operating Income (in millions):**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Specialty Nutrition Systems | $**23.1** | $21.1 |
| Pain Management and Recovery | **(1.8)** | 0.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Segment Operating Income | **21.3** | 21.3 |
| Corporate and Other | **(12.4)** | (11.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Operating Income | $**8.9** | $10.3 |

---

The above-described items drove segment operating income to $21.3 million for both the three months ended March 31, 2026 and 2025. Consolidated operating income was $8.9 million for the three months ended March 31, 2026, compared to $10.3 million for the three months ended March 31, 2025.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

*Adjusted Operating Income*

A reconciliation of adjusted operating income, a non-GAAP measure, to operating income is provided in the table below (in millions):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Operating Income, as reported (GAAP) | $**8.9** | $10.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisition and integration-related charges | **0.9** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Post-RH Divestiture restructuring | **1.8** | 3.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Litigation and legal | **—** | (1.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangibles amortization | **4.6** | 5.1 |
| Adjusted operating income (non-GAAP) | $**16.2** | $17.1 |

---

The items noted in the table above are described below:

*<u>Acquisition and integration-related charges</u>:* We had $0.9 million of acquisition or integration-related charges in the three months ended March 31, 2026, related to our acquisition of Nexus in September 2025. We had no acquisition or integration-related charges for the three months ended March 31, 2025.

*<u>Post-RH Divestiture restructuring charges:</u>* During 2024, following the RH Divestiture, we initiated the Plan. In the three months ended March 31, 2026 and 2025, we incurred expenses of $1.8 million and $3.1 million, respectively, related to the Plan, which primarily consisted of employee severance and benefits costs, professional services fees and equipment write-offs. See Note 2, "Restructuring Activities" in the accompanying notes to the condensed consolidated financial statements.

*<u>Litigation and legal</u>:* We had no costs for litigation matters in the three months ended March 31, 2026. In the three months ended March 31, 2025, we recovered $1.4 million related to a settlement for a customer claim from 2023.

*<u>Intangibles amortization</u>:* Intangibles amortization is related primarily to intangibles acquired in business acquisitions and was $4.6 million for the three months ended March 31, 2026, and $5.1 million for the three months ended March 31, 2025.

*Interest Expense*

Interest expense consists of interest accrued and amortization of debt issuance costs on our revolving credit facility net of interest capitalized on long-term capital projects. See Note 7, "Debt" in Item 1 of this Form 10-Q. Interest expense was $1.5 million for the three months ended March 31, 2026, compared to $2.1 million in the three months ended March 31, 2025. Our outstanding debt balances, net of unamortized discounts, were $98.2 million and $100.5 million as of March 31, 2026 and December 31, 2025, respectively.

*Income Taxes*

The income tax provision was $2.5 million in the three months ended March 31, 2026, compared to $3.1 million in the three months ended March 31, 2025. Our effective tax rate was 32.9% in the three months ended March 31, 2026. For the three months ended March 31, 2025, our effective tax rate was 32.0%.

**Liquidity and Capital Resources**

*General*

Our primary sources of liquidity are cash on hand provided by operating activities and amounts available with our Revolving Credit Facility under our Credit Agreement. We expect our operating cash flow will be sufficient to meet our working capital requirements and fund capital expenditures in the next twelve months. In addition, with our borrowing capacity, we expect to have the ability to fund capital expenditures and other investments necessary to grow our business for the foreseeable future for both our domestic and international operations.

As of March 31, 2026, $48.1 million of our $65.6 million of cash and cash equivalents was held by foreign subsidiaries. We consider the undistributed earnings of our foreign subsidiaries to be indefinitely reinvested overseas and currently do not have plans to repatriate such earnings. We do not expect restrictions on repatriation of cash held outside of the United States to have a material effect on our overall liquidity, financial condition or results of operations for the foreseeable future.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

Cash and cash equivalents decreased by $24.2 million to $65.6 million as of March 31, 2026, compared to $89.8 million as of December 31, 2025. The decrease was primarily driven by $12.3 million of cash used in operating activities, $4.3 million of capital expenditures, $3.4 million of investments in non-affiliates, and payments of $2.3 million on our term loan.

In the prior year, cash and cash equivalents decreased by $10.7 million to $97.0 million as of March 31, 2025. The decrease was primarily driven by payments of $25.0 million on our revolving credit facility, $6.7 million of capital expenditures, $2.4 million of investments in non-affiliates, and payments of $2.3 million on our term loan. This was partially offset by $25.7 million of cash provided by operations.

*Long-Term Debt*

On June 24, 2022, we entered into a credit agreement (the "Credit Agreement") with certain lenders which established credit facilities in an aggregate principal amount of $500.0 million, consisting of a five-year senior secured term loan of $125.0 million (the "Term Loan Facility") and a five-year senior secured revolving credit facility allowing borrowings of up to $375.0 million, with a letter of credit sub-facility in an amount of $75.0 million (the "Revolving Credit Facility"). All obligations under the Credit Agreement and certain hedging agreements and cash management arrangements thereunder are: (i) guaranteed by each of the Company's direct and indirect, existing and future, material wholly owned domestic subsidiaries ("Guarantors") and (ii) secured by a first priority lien on substantially all the assets of the Company and the Guarantors. The Credit Agreement contains an accordion feature that allows us to incur incremental term loans under the Term Loan Facility or under new term loan facilities or to increase the amount of the commitments under the Revolving Credit Facility, including through the establishment of one or more tranches under the Revolving Credit Facility. The Credit Agreement will mature on June 24, 2027.

Borrowings under the Term Loan Facility and Revolving Credit Facility bear interest at our option at either: (i) an adjusted term secured overnight financing rate ("SOFR"), plus a margin ranging between 1.50% to 2.00% per annum, depending on our consolidated total leverage ratio; (ii) an adjusted daily simple SOFR rate, plus a margin ranging between 1.50% to 2.00% per annum, depending on our consolidated total leverage ratio; or (iii) a base rate (calculated as the greatest of (a) the prime rate, (b) the NYFRB rate (being the greater of the federal funds effective rate or the overnight bank funding rate) plus 0.50%, and (c) the one month adjusted term SOFR rate plus 1.00%), plus a margin ranging between 0.50% to 1.00% per annum, depending on our consolidated total leverage ratio. The unused portion of the Revolving Credit Facility will be subject to a commitment fee ranging between 0.20% to 0.25% per annum, depending on our consolidated total leverage ratio.

The Credit Agreement requires compliance with certain customary operational and financial covenants. As of March 31, 2026, we were in compliance with these covenants. In addition, the Credit Agreement contains certain other customary limitations on our ability to, among other things: incur additional indebtedness; pay dividends on or repurchase or redeem our capital stock; make loans, investments and acquisitions; sell, transfer or otherwise dispose of assets; guarantee other obligations; create or grant liens; and enter into certain types of transactions with affiliates. Notwithstanding such limitations, the Credit Agreement allows us to pay dividends, repurchase stock and make investments up to an "Available Amount," as defined in the Credit Agreement, provided no event of default has occurred and certain financial ratios have been achieved on a pro forma basis.

See Note 7, "Debt" in Item 1 of this Form 10-Q for further details regarding our debt agreements.

**Critical Accounting Policies and Use of Estimates**

Our financial statements are prepared by applying certain accounting policies. See Note 1, "Accounting Policies" in Item 8, "Financial Statements and Supplementary Data" in the Form 10-K, which describes our most significant accounting policies. In addition, our critical accounting policies and estimates are presented under the caption "Critical Accounting Policies and Use of Estimates" in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operation" in the Form 10-K. Certain of these policies require management to make estimates or assumptions that may prove inaccurate or be subject to variations that may significantly affect our reported results and financial position for the period or in future periods. Management views these policies as critical accounting policies. See Note 1, "Accounting Policies" in Item 1 of this Form 10-Q for updates to our critical accounting policies and a discussion of recent accounting pronouncements. In the three months ended March 31, 2026, there were no significant changes to our critical accounting estimates from those disclosed in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operation" in the Form 10-K.

**Item 3.&nbsp;&nbsp;&nbsp;&nbsp;Quantitative and Qualitative Disclosures About Market Risk**

There have been no material changes regarding our market risk position from the information provided under Item 7A – "Quantitative and Qualitative Disclosures About Market Risk" in the Form 10-K.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

**Item 4.&nbsp;&nbsp;&nbsp;&nbsp;Controls and Procedures**

With the participation of management, our Chief Executive Officer (principal executive officer) and our Senior Vice President, Chief Financial Officer (principal financial officer) carried out an evaluation, pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and our Senior Vice President, Chief Financial Officer concluded that our disclosure controls and procedures were operating effectively as of March 31, 2026.

**Changes in Internal Control Over Financial Reporting**

There have been no changes in our internal control over financial reporting that occurred during the three months ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

**PART II – OTHER INFORMATION**

**Item 1.&nbsp;&nbsp;&nbsp;&nbsp;Legal Proceedings**

We are subject to various legal proceedings, claims and governmental inspections, audits or investigations pertaining to issues such as contract disputes, product liability, tax matters, patents and trademarks, advertising, governmental regulations, employment and other matters. At present, although the results of litigation and claims cannot be predicted with certainty, we believe that the ultimate resolution of any pending legal proceeding to which we are a party will not have a material adverse effect on our business, financial condition, results of operations or liquidity.

**Item 1A.&nbsp;&nbsp;&nbsp;&nbsp;Risk Factors**

In addition to the risk factors set forth below and the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors discussed in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2025, which could materially affect our business, financial condition or future results of operations. The risks described below and in our Annual Report on Form 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and results of operations. The information below amends, updates and should be read in conjunction with the risk factors and information disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025.

***Risks Related to the Pending Merger***

We are subject to a number of risks and uncertainties as a result of the Merger, including the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *The Merger may not be completed on the anticipated terms or timeline, or at all.* The completion of the proposed Merger is subject to the satisfaction or waiver of a number of conditions, many of which are beyond our control, including receipt of required regulatory approvals; approval of the Merger Agreement by the affirmative vote of the holder of a majority of the outstanding shares entitled to vote thereon ("Company Stockholder Approval"); and the absence of any law or order prohibiting the transaction. There can be no assurance that these conditions will be satisfied in a timely manner or at all. If the Merger is not completed, we may experience negative impacts, including the diversion of management attention, potential employee attrition and costs incurred in connection with the transaction, without realizing its anticipated benefits. In addition, our stock price may decline to the extent that the current market price reflects a market assumption about the likelihood and timing of the Merger.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *The pendency of the Merger could adversely affect our business and operations.* Uncertainty about the effect of the Merger on employees, customers, suppliers and other stakeholders may have an adverse effect on our business. For example, current and prospective employees may experience uncertainty about their roles following the Merger, which could lead to attrition or difficulty in recruiting. In addition, customers and suppliers may delay or defer decisions, which could have a material adverse effect on our business,results of operations, financial condition and cash flows. Contractual restrictions under the Merger Agreement that require us to operate our business in the ordinary course and limit us from taking certain actions without Parent's consent may also limit our ability to respond to changing market conditions, pursue new opportunities or take other actions that might be beneficial to our business, which in turn could have a material adverse effect on our business, results of operations, financial condition and cash flows.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *The Merger Agreement contains provisions that limit our ability to pursue alternatives.* Under the Merger Agreement, the Company is bound by a "no-shop" provision that restricts our ability to solicit, initiate or knowingly take any action to facilitate or encourage any competing acquisition proposals. While these restrictions are subject to the Board's right, pursuant to the terms of the Merger Agreement, to engage in discussions or negotiations regarding an unsolicited acquisition proposal that is or would reasonably be expected to lead to a Superior Proposal (as defined in the Merger Agreement), these restrictions could limit our ability to pursue potentially more favorable transactions and may discourage other parties from making competing offers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *We may be required to pay a termination fee under certain circumstances.* Upon termination of the Merger Agreement under specified circumstances, including if we terminate the Merger Agreement to enter into an alternative acquisition agreement with respect to a Superior Proposal, the Company will be required to pay to Parent a termination fee of

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

$37,500,000. This obligation could discourage alternative transactions that might otherwise be favorable to our shareholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Litigation relating to the Merger could result in significant costs and delay completion.* We may be subject to lawsuits related to the Merger Agreement and the proposed transaction. Such litigation could result in significant costs, divert management attention and delay or prevent the completion of the Merger.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *If the Merger is completed, our stockholders will forgo the opportunity to realize potential future appreciation in our stock.* Upon completion of the Merger, our stockholders will receive the consideration specified in the Merger Agreement and will no longer participate in any future growth or appreciation of our business.

**Item 2.&nbsp;&nbsp;&nbsp;&nbsp;Unregistered Sales of Equity Securities and Use of Proceeds**

Not applicable

**Item 3.&nbsp;&nbsp;&nbsp;&nbsp;Defaults Upon Senior Securities**

Not applicable

**Item 4.&nbsp;&nbsp;&nbsp;&nbsp;Mine Safety Disclosures**

Not applicable

**Item 5.&nbsp;&nbsp;&nbsp;&nbsp;Other Information**

None.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

**Item 6. &nbsp;&nbsp;&nbsp;&nbsp;Exhibits**

(a)Exhibits

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| <u>[3.1](https://www.sec.gov/Archives/edgar/data/1606498/000160649820000027/avnsform8kex31.htm)</u> | <u>[Second Amended and Restated Certificate of Incorporation of the Company, incorporated by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K filed on May 6, 2020](https://www.sec.gov/Archives/edgar/data/1606498/000160649820000027/avnsform8kex31.htm)</u> |
| <u>[3.2](https://www.sec.gov/Archives/edgar/data/1606498/000160649820000027/avnsform8kex32.htm)</u> | <u>[Sixth Amended and Restated Bylaws of the Company, incorporated by reference to Exhibit 3.2 of the Company's Current Report on Form 8-K filed on May 6, 2020](https://www.sec.gov/Archives/edgar/data/1606498/000160649820000027/avnsform8kex32.htm)</u> |
| <u>[10.1](https://www.sec.gov/Archives/edgar/data/1606498/000160649826000046/avnsform8k_04132026xex21.htm)</u> | <u>[Agreement and Plan of Merger, dated as of April 13, 2026, by and among Avanos Medical, Inc., A-AV Holdco I, Inc. and A-AV MergerSub, Inc., incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed on April 14, 2026](https://www.sec.gov/Archives/edgar/data/1606498/000160649826000046/avnsform8k_04132026xex21.htm)</u> |
| <u>[31(a)](avns1q2026form10qex31a.htm)</u> | <u>[Section 302 CEO Certification, filed herewith](avns1q2026form10qex31a.htm)</u> |
| <u>[31(b)](avns1q2026form10qex31b.htm)</u> | <u>[Section 302 CFO Certification, filed herewith](avns1q2026form10qex31b.htm)</u> |
| <u>[32(a)](avns1q2026form10qex32a.htm)</u>\* | <u>[Section 906 CEO Certification, furnished herewith](avns1q2026form10qex32a.htm)</u> |
| <u>[32(b)](avns1q2026form10qex32b.htm)</u>\* | <u>[Section 906 CFO Certification, furnished herewith](avns1q2026form10qex32b.htm)</u> |
| 101.INS | XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document |
| 101.SCH | XBRL Taxonomy Extension Schema Document |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |

---

\* The certifications attached as Exhibit 32(a) and 32(b) that accompany this Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Avanos Medical, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.

------

<u>[**Table of Contents**](#i3bee11a598f04c268992b039d8ab3883_7)</u><br>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | AVANOS MEDICAL, INC. | AVANOS MEDICAL, INC. |
| | (Registrant) | (Registrant) |
| May 5, 2026 | By: | /s/ Scott M. Galovan |
|  |  | Scott M. Galovan |
|  |  | Senior Vice President, Chief Financial Officer |
|  |  | (Principal Financial Officer) |
| May 5, 2026 | By: | /s/ John J. Hurley |
|  |  | John J. Hurley |
|  |  | Controller |
|  |  | (Principal Accounting Officer) |

---

## Ex-31.A

**Exhibit 31(a)**

**CERTIFICATIONS**

I, David Pacitti, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the "registrant");

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: May 5, 2026 | /s/ David Pacitti |
| | David Pacitti<br>Chief Executive Officer (Principal Executive Officer) |

---

## Ex-31.B

**Exhibit 31(b)**

**CERTIFICATIONS**

I, Scott M. Galovan, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Avanos Medical, Inc. (the "registrant");

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: May 5, 2026 | /s/ Scott M. Galovan |
| | Scott M. Galovan<br>Senior Vice President, Chief Financial Officer<br>(Principal Financial Officer) |

---

## Ex-32.A

**Exhibit 32(a)**

**<u>Certification of Chief Executive Officer</u>**

**<u>Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code</u>**

I, David Pacitti, Chief Executive Officer of Avanos Medical, Inc., certify that, to my knowledge:

(1)the Form 10-Q, filed with the Securities and Exchange Commission on May 5, 2026 ("accompanied report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the accompanied report fairly presents, in all material respects, the financial condition and results of operations of Avanos Medical, Inc.

---

| | |
|:---|:---|
| Date: May 5, 2026 | /s/ David Pacitti |
| | David Pacitti<br>Chief Executive Officer (Principal Executive Officer) |

---

## Ex-32.B

**Exhibit 32(b)**

**<u>Certification of Chief Financial Officer</u>**

**<u>Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code</u>**

I, Scott M. Galovan, Chief Financial Officer of Avanos Medical, Inc., certify that, to my knowledge:

(1)the Form 10-Q, filed with the Securities and Exchange Commission on May 5, 2026 ("accompanied report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the accompanied report fairly presents, in all material respects, the financial condition and results of operations of Avanos Medical, Inc.

---

| | |
|:---|:---|
| Date: May 5, 2026 | /s/ Scott M. Galovan |
| | Scott M. Galovan<br>Senior Vice President, Chief Financial Officer<br>(Principal Financial Officer) |

---

<br>